How to Help Your Patients Find Capivasertib in Stock: A Provider's Guide

How to Help Your Patients Find Capivasertib in Stock: A Provider's Guide

Prescribing Capivasertib (Truqap) is straightforward. Getting it into your patient's hands is often not. As a specialty oncology drug with a complex access pathway, Capivasertib presents logistical challenges that can delay treatment initiation by days or weeks.

This guide provides actionable strategies for oncology providers and practice staff to streamline the Capivasertib fulfillment process, reduce patient wait times, and ensure treatment continuity.

Current Availability of Capivasertib

Capivasertib (Truqap) is not in a manufacturing shortage as of 2026. AstraZeneca's supply chain appears stable, and the drug is available through specialty pharmacy channels.

However, the practical experience for patients often tells a different story. Common delays include:

• Prior authorization processing times of 5–15 business days
• Companion diagnostic (FoundationOne CDx) turnaround of 1–3 weeks
• Specialty pharmacy intake and verification adding 3–7 days
• Insurance denials requiring appeals that can take 2–4 additional weeks

In total, a patient can wait 3–6 weeks or more from the time Capivasertib is first discussed to the time they receive their first supply. For a patient with progressing metastatic breast cancer, every week matters.

Why Patients Can't Find Capivasertib

Understanding the bottlenecks helps you intervene at the right points:

Specialty Pharmacy Requirement

Truqap is not available at retail pharmacies. Patients who attempt to fill at their local pharmacy will be turned away, creating confusion and delay. Clear communication at the point of prescribing can prevent this.

Prior Authorization Complexity

PA requirements for Capivasertib are more complex than for many oncology drugs because of the companion diagnostic requirement. Payers need documentation of:

1. Confirmed HR+/HER2- status
2. PIK3CA, AKT1, or PTEN alteration via FDA-approved test
3. Prior endocrine-based therapy in the metastatic setting (or recurrence within 12 months of adjuvant therapy)

Incomplete submissions are the leading cause of PA delays and denials.

Cost Barriers

At approximately $23,762 per 28-day cycle, even insured patients may face significant copays that cause them to delay filling their prescription. Proactive enrollment in financial assistance programs prevents this.

What Providers Can Do: 5 Steps to Accelerate Access

Step 1: Order Companion Diagnostics Proactively

Don't wait until you're ready to prescribe Capivasertib. If a patient with HR+/HER2- metastatic breast cancer is approaching endocrine therapy failure, order FoundationOne CDx or a comprehensive NGS panel early. This can eliminate 1–3 weeks from the access timeline.

Pro tip: If your institution routinely performs NGS testing at diagnosis of metastatic disease, PIK3CA/AKT1/PTEN status may already be on file.

Step 2: Prepare Prior Authorization Documentation in Advance

Build a PA packet template for Capivasertib that includes:

• Pathology report confirming HR+/HER2- status
• FoundationOne CDx results showing qualifying alterations
• Treatment history documenting prior endocrine therapy and progression
• Letter of medical necessity

Having this ready to submit immediately upon test confirmation can reduce PA processing by up to a week.

Step 3: Enroll Patients in Access 360 at the Time of Prescribing

AstraZeneca's Access 360 program provides comprehensive support including:

• PA navigation and submission assistance
• Specialty pharmacy coordination
• Co-pay savings enrollment (commercially insured patients may pay $0/month)
• AZ&Me Patient Assistance Program for uninsured/underinsured patients

Enroll at MyAccess360.com or call 844-275-2360. Many practices designate a staff member to handle Access 360 enrollment for all AstraZeneca products.

Step 4: Use Medfinder to Identify Available Pharmacies

Medfinder for Providers allows your staff to check which specialty pharmacies currently have Capivasertib in stock. This is particularly useful when:

• Your patient's preferred specialty pharmacy has a long processing queue
• You need to transfer a prescription to a faster-fulfilling pharmacy
• A patient is transitioning between insurance plans

Step 5: Set Up Refill Monitoring

Treatment interruptions are a real risk with specialty pharmacy fulfillment. Implement a workflow to:

• Flag refill dates 10–14 days in advance
• Confirm PA renewal status before each cycle
• Contact the specialty pharmacy proactively if there are processing delays
• Maintain open communication with the patient about their supply

Alternatives to Consider

If Capivasertib access is significantly delayed and the patient's disease is progressing, consider whether an alternative therapy may be appropriate as a bridge or substitution:

• Alpelisib (Piqray): PI3K inhibitor for PIK3CA-mutated tumors, used with Fulvestrant
• Inavolisib (Itovebi): PI3Kα inhibitor for PIK3CA-mutated tumors, used with Palbociclib and Fulvestrant
• Everolimus (Afinitor): mTOR inhibitor, does not require specific mutations, generic available
• Elacestrant (Orserdu): SERD for ESR1-mutated tumors

For a detailed comparison, see our article on alternatives to Capivasertib.

Workflow Tips for Oncology Practices

Create a Specialty Drug Access Checklist

Standardize the process across your practice:

1. ☐ Companion diagnostic ordered and results received
2. ☐ PA documentation prepared and submitted
3. ☐ Patient enrolled in Access 360
4. ☐ Financial assistance application submitted (if applicable)
5. ☐ Specialty pharmacy selected and prescription sent
6. ☐ Patient contacted with expected timeline
7. ☐ Refill monitoring schedule set up

Designate a Specialty Pharmacy Liaison

Having one staff member who owns the relationship with specialty pharmacies and manufacturer support programs can dramatically improve turnaround times. This person becomes the single point of contact and builds expertise that benefits all patients on specialty drugs.

Communicate Timelines to Patients

Set realistic expectations at the time of prescribing. Let patients know that it may take 2–4 weeks (or more) to receive their first supply of Capivasertib, and explain what's happening during that time. This reduces anxiety and prevents patients from feeling "lost" in the system.

Final Thoughts

Capivasertib access challenges are administrative, not clinical. The drug is available — the barriers are insurance logistics, specialty pharmacy workflows, and cost. By building efficient processes and leveraging manufacturer support, your practice can significantly reduce the time between prescribing and treatment initiation.

For more provider-focused resources, visit Medfinder for Providers. For a guide on the broader availability picture, see our Capivasertib shortage briefing for providers.